Biomarkers and novel agents in esophago-gastric cancer

are we making progress?

Asa Dahle-Smith, Russell D. Petty (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

    Original languageEnglish
    Pages (from-to)1103-1119
    Number of pages17
    JournalExpert Review of Anticancer Therapy
    Volume15
    Issue number9
    DOIs
    Publication statusPublished - 2015

    Fingerprint

    Stomach Neoplasms
    Biomarkers
    Climate
    Immune System
    Intercellular Signaling Peptides and Proteins
    Delivery of Health Care
    Drug Therapy
    Survival
    Therapeutics

    Keywords

    • Biomarkers
    • Esophageal cancer
    • Gastric cancer
    • Targeted agents
    • Translational medicine

    Cite this

    @article{5febefd474864d06abec716c80e1a610,
    title = "Biomarkers and novel agents in esophago-gastric cancer: are we making progress?",
    abstract = "Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.",
    keywords = "Biomarkers, Esophageal cancer, Gastric cancer, Targeted agents, Translational medicine",
    author = "Asa Dahle-Smith and Petty, {Russell D.}",
    year = "2015",
    doi = "10.1586/14737140.2015.1071669",
    language = "English",
    volume = "15",
    pages = "1103--1119",
    journal = "Expert Review of Anticancer Therapy",
    issn = "1473-7140",
    publisher = "Informa Healthcare",
    number = "9",

    }

    Biomarkers and novel agents in esophago-gastric cancer : are we making progress? / Dahle-Smith, Asa; Petty, Russell D. (Lead / Corresponding author).

    In: Expert Review of Anticancer Therapy, Vol. 15, No. 9, 2015, p. 1103-1119.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Biomarkers and novel agents in esophago-gastric cancer

    T2 - are we making progress?

    AU - Dahle-Smith, Asa

    AU - Petty, Russell D.

    PY - 2015

    Y1 - 2015

    N2 - Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

    AB - Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

    KW - Biomarkers

    KW - Esophageal cancer

    KW - Gastric cancer

    KW - Targeted agents

    KW - Translational medicine

    UR - http://www.scopus.com/inward/record.url?scp=84940607603&partnerID=8YFLogxK

    U2 - 10.1586/14737140.2015.1071669

    DO - 10.1586/14737140.2015.1071669

    M3 - Article

    VL - 15

    SP - 1103

    EP - 1119

    JO - Expert Review of Anticancer Therapy

    JF - Expert Review of Anticancer Therapy

    SN - 1473-7140

    IS - 9

    ER -